Children's Hospital of Philadelphia leads or participates in hundreds of clinical research studies and clinical trials. Many of the studies that are currently enrolling patients can be found in this database. Use this finder to learn more about the purpose of these studies and clinical trials, find out who can participate, and tell us you're interested in enrolling.
21 - 30 of 139
Patients with who have had Fontan surgery are at risk for the development of liver fibrosis and cirrhosis. New MRI based imaging techniques allow for non-invasive assessment of liver stiffness and fibrosis. These methods have been used in other diseases, but have not been studied in those who have undergone the Fontan operation. In this study we will test the feasibility of MRI based methods for the assessment of liver disease, and compare the results of these studies to those obtained from clinical liver biopsy.
This is a randomized controlled trial that tests whether a program designed to maintain a high fluid intake decreases kidney stone recurrence. Patients 12 years of age or older who have had a kidney stone in the last 3 years may be eligible.
To identify the underlying causes of bone marrow failure diseases for the purpose of developing and modifying treatment and diagnosis procedures.
Announcing a new diet trial for patients with an established diagnosis of UC. Patients ages 8-19 who have mild and stable disease and have never taken a biologic medication (a class of medications including infliximab and adalimumab) might be eligible. For more information, please contact the IBD Center at IBDResearch@email.chop.edu, or call Lindsay Besecker at (267)-426-8414.
This study is a trial comparing the effects of erenumab to placebo in children ages 6-17 years old with migraine 15 days per month or more. Eligible participants will be given either erenumab or placebo, assigned randomly (like the flip of a coin), followed by an open-label phase in which all participants receive erenumab. Erenumab has been FDA-approved for use in adults to decrease the frequency of migraine. Patients may be eligible to participate if they have had migraine for at least one year, and agree to come to CHOP's main hospital for several study visits. Patients whose headache started suddenly (New Daily Persistent Headache), patients whose headache started after a concussion (Post-Traumatic Headache), and patients with severe depression are not eligible for this study.
The purpose of this research study is to collect information over time in juvenile SpA and back pain patients. The information from this study will be used to better understand these conditions in children as well as improve treatment guidelines. The procedures include questionnaires, medical record review, and optional biospecimen contributions (blood).
The goal of the study extension is to see whether the incretin hormone GIP increases insulin secretion in individuals with CF and normal glucose tolerance compared to individuals without CF and normal glucose tolerance. This study includes 3 or 4 visits.
In this study we are using new biologic features, in addition to the standard risk factors, to help decide which subjects need treatment and what the best treatment is. (Subjects are people who agree to take part in this study.) Subjects will be put into 1 of 3 different treatment groups, labeled as Group A, B and C. The group that you are put in will determine the treatment that you get.
This study involves the collection of medical information and samples from people with suspected leukodystrophies and their relatives to help clarify the type of the leukodystrophies and significantly advance our understanding of the cause of these diseases, the best tools to diagnosis them, and the best way to manage these conditions. Participating involves the collection of biological samples (like blood) and the collection of information about you (from your medical records, interviews, and questionnaires). Participation may also include research genetic testing. You may be asked to respond to surveys to describe the impact of the leukodystrophy on you/your family. Participation timing can vary, depending on what you're asked to do. We will discuss this with you before asking you to agree.
This study looks to assess how celiac disease affects the quality of life of patients between the ages of 13-18. We are looking to recruit 100 patients who are in their first year of diagnosis and their parents. If the above criteria apply to you, you may be eligible to take part in the study.